Acrivon Therapeutics, Inc. 8-K

What Happened
Acrivon Therapeutics, Inc. (ACRV) filed a Form 8‑K (Item 7.01) disclosing a Regulation FD investor webcast and conference call held on January 8, 2026, from about 8:30 a.m. to 9:00 a.m. ET. The company posted the presentation used in the event (the "January 8, 2026 Data Update") on its Investors & Media site (ir.acrivon.com). The update contains ACR-368 clinical data and program updates plus initial clinical data for ACR-2316. The presentation is attached to the filing as Exhibit 99.1. The 8‑K was signed by CEO Peter Blume‑Jensen.

Key Details

• Event: Corporate webcast and conference call on January 8, 2026, ~8:30–9:00 a.m. ET.
• Materials posted: "January 8, 2026 Data Update" presentation available at ir.acrivon.com and attached as Exhibit 99.1 to the 8‑K.
• Data disclosed: ACR-368 clinical data and program updates; initial clinical data for ACR-2316.
• Filing type: Form 8‑K, Regulation FD Disclosure (Item 7.01); signed by Peter Blume‑Jensen, M.D., Ph.D., CEO.

Why It Matters
This filing informs investors that Acrivon publicly shared new clinical data on two programs—ACR-368 (additional data and program status) and ACR-2316 (initial clinical readout). For investors, these clinical updates can affect program timelines, development risk perception, and future value expectations for the company’s oncology pipeline. The presentation availability under Regulation FD ensures all investors have simultaneous access to the same material information.